Keratoconus is an eye disease in which the cornea becomes cone shaped. Vision worsens as progressively stronger eyeglass prescriptions do not fully correct vision. The problem is a weakness in the structure of the front eye wall.
To strengthen the cornea and stop keratoconus progression a single office treatment with low dose UV light and eye drops of riboflavin (vitamin B2) is under US FDA clinical trials. The process, called crosslinking and abbreviated CXL, causes a structural change in the cornea. The treatment, created in Switzerland, has been performed since 1998 outside the U.S.
The purpose of CXL is to prevent further deterioration of the cornea and the vision from keratoconus.The vitamin B2 and low dose UV light produce a chemical change in the clear skeleton of the cornea. The process makes new structural bonds. The effect, shown in over 100 medical journal articles, is to prevent further structural collapse of the cornea.
Intacs are tiny arc-shaped plastic braces that are surgically placed within the cornea to reshape the cornea.
Intacs are FDA approved for keratoconus and may improve vision by making the cornea more round again.
Intacs insertion is done with just eye drop anesthesia and mild calming sedation.
It is done in the office-based surgery center where lasik is performed.
Both Intacs Insertion and Corneal Transplantation also are performed at The Center for Corrective Eye Surgery. Crosslinking (CXL) may help prevent further change in eye shape from Keratoconus after treatment by Intacs Insertion or Corneal Transplantation.
Dr. Robert Epstein
Robert L. Epstein MD